Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013

CRANBURY, N.J., May 8, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14, 2013. The conference call will include an update on development of bremelanotide for female sexual dysfunction, including plans for Phase 3 clinical trials and results of the end-of-Phase 2 meeting with the U.S. Food and Drug Administration.



Schedule for the Financial Results Press Release, Conference Call / Webcast 



  • 3Q Fiscal Year 2013 Financial Results Press Release   

5/14/2013 at 7:30 a.m. ET

       

  • 3Q Fiscal Year 2013 Conference Call-Live                             
    Domestic Dial-In Number                                                        
    International Dial-In Number                                                    
    Passcode                                                                                 

5/14/2013 at 11:00 a.m. ET

1-888-427-9419

1-719-457-2648

8591699
            

  • 3Q Fiscal Year 2013 Conference Call-Replay             
    Domestic Dial-In Number                                                        
    International Dial-In Number                                                    
    Passcode                                                                                 

5/14/2013-5/21/2013

1-888-203-1112

1-719-457-0820

8591699
         

  • Webcast Live and Replay Access                                            

http://www.palatin.com
         

The webcast and replay can be accessed by logging on to the “Investor/Media Center-Webcasts”

section of Palatin’s website at http://www.palatin.com



About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com or follow us on Twitter at http://twitter.com/PalatinTech.

SOURCE Palatin Technologies, Inc.

Scroll to Top